VarmX: Innovative Approaches in Anticoagulation Reversal Showcased at Biopharmaceutical Industry Events

VarmX Announces Plans to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company focused on developing innovative approaches for reversing anticoagulation, will be attending two prominent events in the European biopharmaceutical industry. Firstly, the LSX World Congress on April 29-30 will feature 1:1 partnering opportunities and VarmX will be attending to engage with investors and other biopharmaceutical companies. Secondly, Martijn Negen, VarmX’s SVP Global Commercial Strategy & Business Development, will present at Bio€quity Europe on May 12-14.

VarmX is a spin-off from the Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, an expert in hemostasis and thrombosis. The company’s lead compound VMX-C001 is a modified recombinant blood factor X developed for treating severe spontaneous bleeding and preventing bleeding during urgent surgeries in patients using oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.

VarmX is backed by a strong group of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter. For media inquiries please contact Instinctif Partners at Melanie Toyne-Sewell / Katie Duffell Tel: +44 20 7457 2020 Email: VarmX@instinctif.com or if you wish to meet with the VarmX Team at either of these upcoming events or obtain more information please contact info@varmx.com

Leave a Reply